Concert Pharmaceuticals, Inc.








Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise



Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Market Cap: 310 Million

Primary Exchange: NASDAQ


Shares Outstanding: 29.7 Million

Float: 26.6 Million

Dividend: (%)

Beta: 0.916466196956063

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 684 trading days

From: 2017-12-19 To: 2020-08-10

Lowest Point:

Concert Pharmaceuticals: Cheap Valuation With Multiple Programs Moving Forward

via: SeekingAlpha at 2019-06-13 09:46:22:000

Shares of Concert Pharmaceuticals ( CNCE ) have provided quite the roller coaster ride for investors. The stock was a winner for us the first time around , as it tripled after my original recommendation (due to a lucrative deal inked with Vertex Pharmaceuticals (VRTX)). Subsequent recommendat… read more...

Concert Pharma's CTP-692 shows favorable safety profile in early-stage studies

via: SeekingAlpha at 2019-06-12 04:12:37:000

Concert Pharmaceuticals (NASDAQ: CNCE ) announces that results from single-dose and multiple-ascending-dose Phase 1 trials evaluating the safety, tolerability and pharmacokinetics of CTP-692 in healthy volunteers showed that it was well-tolerated across all dose ranges tested, including th… read more...

Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers

via: Business Wire at 2019-06-12 03:00:00:000

The Company Expects to Initiate a Phase 2 Trial in Patients with Schizophrenia in the Fourth Quarter of 2019 Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported positive results from two studies in its Phase 1 program evaluating CTP-692, a novel deuterium-modified form of … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud